Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ILEANA M RODICIO

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1689638629
CMS profile
166724
Location
MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$6,618.10

159 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $4,658.00 154
Consulting Fee $1,743.37 2
Education $133.26 2
Travel and Lodging $83.47 1

By paying entity

PY2025 · entire year · sorted by reported total

Page 4 of 4; records 151–159 of 159 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ILEANA M RODICIO

NPI 1689638629 · CMS profile ID 166724

Allopathic & Osteopathic Physicians / Allergy & Immunology

MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–159 of 159 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1689638629?year=2025&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ILEANA M RODICIO, NPI 1689638629, CMS profile ID 166724. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–159 of 159 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1689638629?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). ILEANA M RODICIO, NPI 1689638629, CMS profile ID 166724. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–159 of 159 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1689638629?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
ILEANA M RODICIO, NPI 1689638629, CMS profile ID 166724, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–159 of 159 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1689638629?year=2025&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

159 matching records · $6,618.10 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 159 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–159 of 159.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $28.4101/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1214795780 CMS
AstraZeneca Pharmaceuticals LP $29.1401/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1214805866 CMS
GENZYME CORPORATION $38.8501/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233359555 CMS
AstraZeneca Pharmaceuticals LP $21.7001/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1214784012 CMS
Amgen Inc. $18.7801/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228380376 CMS
AstraZeneca Pharmaceuticals LP $18.6101/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1214792959 CMS
BioCryst US Sales Co., LLC $24.3801/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222017264 CMS
AstraZeneca Pharmaceuticals LP $58.2901/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1214779168 CMS
AstraZeneca Pharmaceuticals LP $18.7201/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1215350626 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,371.62 98
PY2020 $1,132.79 50
PY2021 $2,255.90 83
PY2022 $2,986.55 115
PY2023 $3,429.08 125
PY2024 $5,561.03 131
PY2025 $6,618.10 159

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $872,517.02 89
PY2024 Principal investigator $450,549.55 44
PY2023 Principal investigator $192,559.40 8
PY2022 Principal investigator $146,204.07 24
PY2021 Principal investigator $644,737.17 108
PY2020 Recipient $7,527.29 1
PY2020 Principal investigator $783,808.43 36
PY2019 Recipient $1,525.00 1
PY2019 Principal investigator $637,459.69 47

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

89 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,996.36 12/18/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048202
Principal investigator 1 GlaxoSmithKline, LLC. $1,838.03 12/11/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192170060
Principal investigator 1 GlaxoSmithKline, LLC. $1,010.81 12/11/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192170457
Principal investigator 1 GlaxoSmithKline, LLC. $275.74 12/11/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192172291
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $346.95 12/11/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048196
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $375.00 12/11/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048198
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,252.57 12/11/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048200
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 12/05/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192170449
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 12/05/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192170466
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $375.00 12/04/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048194
Principal investigator 1 GlaxoSmithKline, LLC. $72.00 11/24/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192166856
Principal investigator 1 GlaxoSmithKline, LLC. $8,777.00 11/24/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192170453
Principal investigator 1 GlaxoSmithKline, LLC. $9,540.63 11/21/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192170054
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 11/20/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192170470
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $12,825.71 11/20/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048192
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $204.60 11/19/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048260
Principal investigator 1 GlaxoSmithKline, LLC. $312.00 11/13/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192170064
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 11/12/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048258
Principal investigator 1 GlaxoSmithKline, LLC. $267.00 11/05/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192172275
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $346.95 10/30/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048190
Principal investigator 1 GlaxoSmithKline, LLC. $638.80 10/28/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192170046
Principal investigator 1 GlaxoSmithKline, LLC. $8,961.48 10/23/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192170072
Principal investigator 1 GlaxoSmithKline, LLC. $7,167.82 10/23/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192172282
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,498.18 10/23/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048188
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $981.46 10/14/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048186
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $693.90 10/09/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048184
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $11,192.21 09/25/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048180
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,284.55 09/25/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048182
Principal investigator 1 GlaxoSmithKline, LLC. $21,511.71 09/24/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192110985
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,000.00 09/11/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048178
Principal investigator 1 GlaxoSmithKline, LLC. $184.63 09/05/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA REREARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192163133
Principal investigator 1 GlaxoSmithKline, LLC. $1,010.81 08/27/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192170068
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,996.36 08/27/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048176
Principal investigator 1 GlaxoSmithKline, LLC. $5,093.41 08/25/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA REREARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192166467
Principal investigator 1 GlaxoSmithKline, LLC. $216.00 08/25/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192166848
Principal investigator 1 GlaxoSmithKline, LLC. $5,927.00 08/25/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192170462
Principal investigator 1 GlaxoSmithKline, LLC. $21,585.96 08/22/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192166844
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $12,210.78 08/21/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048174
Principal investigator 1 GlaxoSmithKline, LLC. $5,309.88 08/06/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192172300
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,498.18 08/06/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048172
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $364.95 08/06/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048234
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 08/05/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048256
Principal investigator 1 GlaxoSmithKline, LLC. $624.00 08/01/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192172287
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,897.11 07/24/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048168
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,494.54 07/24/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048170
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,498.18 07/24/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048232
Principal investigator 1 GlaxoSmithKline, LLC. $1,822.18 07/18/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192170050
Principal investigator 1 GlaxoSmithKline, LLC. $22,910.00 07/18/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192172304
Principal investigator 1 GlaxoSmithKline, LLC. $1,625.86 07/16/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA REREARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192166835
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 07/15/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048254
Principal investigator 1 GlaxoSmithKline, LLC. $2,500.00 07/02/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192170480
Principal investigator 1 GlaxoSmithKline, LLC. $10,800.00 06/25/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192166852
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,947.45 06/24/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048166
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $600.00 06/24/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048230
Principal investigator 1 GlaxoSmithKline, LLC. $30,144.51 06/23/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192172308
Principal investigator 1 GlaxoSmithKline, LLC. $18,556.68 06/20/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA REREARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192166832
Principal investigator 1 Novartis Pharmaceuticals Corporation $167,657.42 06/15/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190307787
Principal investigator 1 GlaxoSmithKline, LLC. $2,050.00 06/06/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA REREARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192166463
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 06/05/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA REREARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192163152
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 06/05/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048252
Principal investigator 1 GlaxoSmithKline, LLC. $31,689.15 05/28/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA REREARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192166493
Principal investigator 1 GlaxoSmithKline, LLC. $1,010.81 05/22/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192166485
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $250.00 05/22/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048162
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,000.00 05/22/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048164
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $15,920.88 05/15/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048160
Principal investigator 1 GlaxoSmithKline, LLC. $184.63 04/28/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA REREARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192166489
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,205.26 04/24/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048158
Principal investigator 1 GlaxoSmithKline, LLC. $26,415.98 04/22/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA REREARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192166828
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,300.00 04/16/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA CARE
A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 1185547285
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 04/10/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA REREARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192166480
Principal investigator 1 GlaxoSmithKline, LLC. $29,334.23 03/21/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA REREARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192163148
Principal investigator 1 GlaxoSmithKline, LLC. $184.63 03/21/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA REREARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192166477
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 03/20/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192110978
Principal investigator 1 GlaxoSmithKline, LLC. $14,420.01 03/20/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192170475
Principal investigator 1 GlaxoSmithKline, LLC. $250.00 03/20/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192172296
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $444.83 03/20/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048156
Principal investigator 1 GlaxoSmithKline, LLC. $184.55 03/06/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA REREARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192166473
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,041.24 02/27/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048154
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 02/24/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA REREARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192163140
Principal investigator 1 GlaxoSmithKline, LLC. $26,240.90 02/24/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA REREARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192163143
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $204.60 02/21/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048262
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $500.00 02/06/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048406
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,198.19 02/06/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048409
Principal investigator 1 GlaxoSmithKline, LLC. $4,554.90 01/30/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192170076
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,368.96 01/16/2025 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048404
Principal investigator 1 GlaxoSmithKline, LLC. $18,082.88 01/09/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA REREARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192166840
Principal investigator 1 AstraZeneca Pharmaceuticals LP $15,458.40 01/03/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA CARE
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 1185547287
Principal investigator 1 Novartis Pharmaceuticals Corporation $74,670.39 01/01/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U No dispute reported 06/30/2026 1190307785
Principal investigator 1 Novartis Pharmaceuticals Corporation $131,606.45 01/01/2025 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately co No dispute reported 06/30/2026 1190307793